Clinical trials: Meningitis, Bacterial
Infections, Meningococcal
Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants
The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to…
- Trial name
- NCT02106390
- Testing
- Meningococcal group B Vaccine, rMenB+OMV NZ, Meningococcal ACWY Conjugate Vaccine, MenACWY
- Where
- 7 sites in Argentina, Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Meningococcal Meningitis
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
- Trial name
- NCT01214837
- Testing
- MenACWY-CRM, Routine Vaccines
- Where
- 40 sites in United States, Canada
- Volunteers
- 751 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal Infection
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
The purpose of this trial is to describe the safety and antibody response to revaccination with Menactra vaccine in persons who received their first dose at ≥11 years of age.
- Trial name
- NCT01442675
- Testing
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
- Where
- 15 sites in United States
- Volunteers
- 834 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology)
Adjunctive Doxycycline for Central Nervous System Tuberculosis
Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary…
- Conditions
- Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System, Tuberculosis; Meningoencephalitis (Etiology)
- Trial name
- DIRECT (NCT06446245)
- Testing
- Doxycycline, Anti Tuberculosis Drug, Adjunctive corticosteroid
- Where
- 6 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Meningitis, Meningococcal
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
The purpose of this study was to collect large volumes of matched pairs of pre- and post-vaccination sera from healthy subjects who administered GlaxoSmithKline (GSK) Biologicals' vaccine against meningitis- MenACWY vaccine…
- Trial name
- NCT03493919
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- Where
- 6 sites in Australia, Germany
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cryptococcal Meningitis
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
- Trial name
- NCT04532463
- Testing
- Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
- Where
- Burma
- Volunteers
- 30 people
- Sponsor
- University of Pharmacy, Yangon
Tuberculosis, Meningitis
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Contezolid is a novel oxazolidinone antibiotic developed by Shanghai Mengke Pharmaceutical Co., Ltd., which successfully went public in 2021.
- Trial name
- NCT06811025
- Testing
- Contezolid, Linezolid (LZD)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis, Tuberculous Meningitis
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
The investigators will conduct a randomized, double blind, placebo controlled trial of adjunctive dexamethasone in the initial (6-8 weeks) treatment of tuberculous meningitis in Vietnamese adults.
- Conditions
- Tuberculosis, Tuberculous Meningitis, Drug-Induced Liver Injury, HIV
- Trial name
- NCT03092817
- Testing
- Dexamethasone
- Where
- 6 sites in Indonesia, Vietnam
- Volunteers
- 520 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months
The goal of this clinical trial is to evaluate the immunogenicity, safety, and persistence of the immune response of a group ACYW135 meningococcal conjugate vaccine in healthy children aged 6 to 11 months.
- Trial name
- NCT07505823
- Testing
- experimental vaccine, Active Comparator vaccine
- Where
- 2 sites in China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Meningitis, Bacterial
A Controlled Study to Assess Safety, Colonisation and Immunogenicity of Reconstituted Lyophilised Neisseria Lactamica
This study is part of a series of projects to develop and test new vaccines for meningitis. Previously researchers have given nose drops containing N.
- Trial name
- Lac5-Nasal (NCT04135053)
- Testing
- Lyophilised Neisseria lactamica
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG
Meningococcal Meningitis, Tetanus
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine.
- Conditions
- Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis
- Trial name
- NCT00355121
- Testing
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 26 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Sanofi
Cryptococcal Meningitis
Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety trial to evaluate Mycograb®.
- Trial name
- NCT00324025
- Testing
- Mycograb
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Meningitis, Meningococcal Infection
Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children
This is a passive-surveillance study that will accrue subjects for surveillance. For each accrued subject, surveillance for outcomes will continue for six months following the first dose.
- Trial name
- NCT01689155
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Meningitis, Meningococcal Infection
Dose Comparison Study of Menactra® in US Children
To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.
- Conditions
- Meningitis, Meningococcal Infection, Neisseria Meningitidis
- Trial name
- NCT00700635
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
- Where
- 15 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Disease
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea
The aim of the study is to assess safety and immunogenicity of a single dose of Menactra® in support of registration of the vaccine in South Korea.
- Trial name
- NCT01642589
- Testing
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- Where
- 7 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Meningitis
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
The aim of this study was to collect further information regarding an increase immune response of SP284 after an additional dose in Japanese participants.
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02591290
- Testing
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate
- Where
- Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children
This was an open-label, multi-center study to describe the immune persistence of the priming dose and describe the immunogenicity and safety of a booster dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus…
- Trial name
- NCT03476135
- Testing
- MenACYW conjugate vaccine
- Where
- 8 sites in Finland
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Epidemic Meningitis
A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)
This study included 180 trial participants who had previously taken part in the Phase IIIb clinical trial of the ACYW135 group meningococcal polysaccharide-conjugated vaccine (CRM197 carrier) for children aged 4-6 years (Protocol…
- Trial name
- NCT07743411
- Testing
- Previously vaccinated with MCV4 (CanSino), Previously vaccinated with MPSV4 (LvZhu)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.